S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
Lowest-Rated StocksLowest-Rated
NASDAQ:FATE

Fate Therapeutics (FATE) Competitors

$5.13
+0.09 (+1.79%)
(As of 05/26/2023 ET)
Compare
Today's Range
$5.00
▼
$5.19
50-Day Range
$4.89
▼
$6.59
52-Week Range
$4.02
▼
$37.13
Volume
1.67 million shs
Average Volume
2.32 million shs
Market Capitalization
$504.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.24
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

FATE vs. TNYA, AGEN, OMGA, VYGR, AMAM, AUTL, ITOS, AURA, TARS, and MGTX

Should you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Tenaya Therapeutics (TNYA), Agenus (AGEN), Omega Therapeutics (OMGA), Voyager Therapeutics (VYGR), Ambrx Biopharma (AMAM), Autolus Therapeutics (AUTL), iTeos Therapeutics (ITOS), Aura Biosciences (AURA), Tarsus Pharmaceuticals (TARS), and MeiraGTx (MGTX). These companies are all part of the "biological products, except diagnostic" industry.

Fate Therapeutics vs.

Fate Therapeutics (NASDAQ:FATE) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Fate Therapeutics presently has a consensus price target of $16.24, suggesting a potential upside of 216.48%. Tenaya Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 168.24%. Given Fate Therapeutics' higher probable upside, equities analysts plainly believe Fate Therapeutics is more favorable than Tenaya Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics
2 Sell rating(s)
15 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.14
Tenaya Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Fate Therapeutics received 464 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. Likewise, 70.94% of users gave Fate Therapeutics an outperform vote while only 60.00% of users gave Tenaya Therapeutics an outperform vote.

CompanyUnderperformOutperform
Fate TherapeuticsOutperform Votes
476
70.94%
Underperform Votes
195
29.06%
Tenaya TherapeuticsOutperform Votes
12
60.00%
Underperform Votes
8
40.00%

Tenaya Therapeutics has lower revenue, but higher earnings than Fate Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$96.30 million5.24-$281.72 million-$2.42-2.12
Tenaya TherapeuticsN/AN/A-$123.67 million-$2.47-2.83

In the previous week, Fate Therapeutics had 2 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Tenaya Therapeutics. Fate Therapeutics' average media sentiment score of 0.69 beat Tenaya Therapeutics' score of 0.43 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Fate Therapeutics Positive
Tenaya Therapeutics Neutral

Fate Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500.

Tenaya Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -171.64%. Fate Therapeutics' return on equity of -45.62% beat Tenaya Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fate Therapeutics -171.64% -45.62% -32.49%
Tenaya Therapeutics N/A -56.59% -49.42%

Summary

Fate Therapeutics beats Tenaya Therapeutics on 10 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FATE vs. The Competition

Export to Excel
MetricFate TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$504.71M$2.58B$4.56B$6.18B
Dividend YieldN/A2.33%2.32%6.15%
P/E Ratio-2.123.0974.1711.55
Price / Sales5.24182.873,695.1886.22
Price / CashN/A16.1297.53107.27
Price / Book1.064.895.037.13
Net Income-$281.72M$53.60M$118.58M$192.91M
7 Day Performance3.01%-0.14%1.09%0.20%
1 Month Performance-15.49%7.02%1.28%1.33%
1 Year Performance-78.24%10.14%19.51%-0.24%

Fate Therapeutics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TNYA
Tenaya Therapeutics
1.9713 of 5 stars		$7.60
+2.2%		$18.00
+136.8%		+5.7%$508.21MN/A-3.08106Short Interest ↑
AGEN
Agenus
2.2715 of 5 stars		$1.52
+2.0%		$7.33
+381.9%		-9.9%$530.30M$98.02M-1.85441Gap Down
OMGA
Omega Therapeutics
2.1917 of 5 stars		$9.66
+0.4%		$9.60
-0.6%		+208.3%$531.49M$2.07M-4.3579News Coverage
Positive News
VYGR
Voyager Therapeutics
2.7222 of 5 stars		$12.37
-10.7%		$16.00
+29.3%		+99.2%$538.59M$40.91M5.43101News Coverage
High Trading Volume
AMAM
Ambrx Biopharma
1.3839 of 5 stars		$14.23
+5.6%		$14.33
+0.7%		+245.1%$549.85M$7.40M0.0070
AUTL
Autolus Therapeutics
2.5228 of 5 stars		$3.19
-0.3%		$8.20
+157.1%		+8.0%$552.09M$6.36M-2.29324Short Interest ↓
High Trading Volume
ITOS
iTeos Therapeutics
2.0534 of 5 stars		$15.44
+0.7%		$39.67
+156.9%		+5.6%$552.13M$267.63M49.8194Short Interest ↑
AURA
Aura Biosciences
1.5871 of 5 stars		$11.73
-0.9%		$24.00
+104.6%		-34.2%$443.39MN/A-5.9252
TARS
Tarsus Pharmaceuticals
2.344 of 5 stars		$16.50
+1.6%		$41.00
+148.5%		+11.0%$442.20M$25.82M-6.7346
MGTX
MeiraGTx
2.6727 of 5 stars		$7.42
+3.8%		$29.33
+295.3%		-20.1%$441.49M$15.92M-2.66287

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:FATE) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -